Pharmacuetical grade ProOmega-D provides exceptionally high levels of the omega-3 fats, EPA and DHA. Each serving provides a total of 1280 mg of omegas.
Professional version of Nordic Naturals' popular Ultimate Omega-D fish oil supplement.
ProOmega-D is in a natural triglyceride form which is 70% more absorbable than the ethyl ester form found in other fish oils.
1000 IU of natural vitamin D3 for strong bones and a healthy immune system.*
Nordic Naturals’ patented "nitrogen processing" ensures that ProOmega-D is 100% pure and fresh. Fresh fish oils are better for the body, and do not create negative side effects such as repeat or burp-back.
100% natural lemon flavor with no fishy smell, taste, or aftertaste.
Third party tested for safety and efficacy – surpassing all international quality standards.
Nordic Naturals ProOmega-D supports healthy cardiovascular and respiratory function, joint flexibility and mobility, and the body’s natural anti-inflammatory response.*
Doctors recommend healthy people consume at least 500mg of DHA and EPA from omega-3 fish oil daily. ProOmega-D makes it easy to get your daily dose of omega-3’s.
* These statements have not been evaluated by the U.S. Food and Drug Administration. This product is not intended to treat, mitigate, diagnose or cure any disease.
Omega-3 LC-PUFA has been shown in a number of clinical studies to help reduce joint discomfort and stiffness1.
In a critical examination of 14 clinical trials in patients with rheumatoid arthritis or joint pain, supplementation with omega-3 LC-PUFA resulted in a decrease in joint pain intensity, duration of morning stiffness, the number painful and tender joints and the use of pain relief medication2.
In a clinical study conducted a Harvard University with patients having retinitis pigmentosa, supplementation with DHA (a component of omega-3 LC-PUFA) along with vitamin A started at the same time had a stronger protective effect again vision loss than vitamin A taken alone3.
Clinical studies show that DHA, a component of omega-3 LC-PUFA, plays a vital role in the optimum function of the retina4.
Human population-based studies have shown that a high intake of omega-3 LC-PUFA is associated with 40% reduced risk of age related macular degeneration (AMD) but this finding has not yet been confirmed in a in clinical intervention study5.
In a human clinical study 120 women aged 40-55 with an average of 2.8 hot flashes/day were given omega-3 LC PUFA or placebo for 8 weeks. The omega-3 group experienced a statistically significant decline of 1.58 hot flashes/day compared to a decline of 0.5 hot flashes/day in the placebo group6.
Based on numerous clinical studies, omega-3 LC-PUFA are widely recommended to keep the heart and blood vessels in good condition7,8.
A critical review of clinical studies conducted at prestigious medical schools showed that omega-3 LC-PUFA can reduce heart rate9.
Numerous high quality clinical studies show that omega-3 LC-PUFA significantly lower blood triglycerides, a risk factor for heart disease10.
Omega-3 LC-PUFA also increases HDL-cholesterol, the good cholesterol, and improves the ratio of LDL-cholesterol to HDL-cholesterol, a beneficial change11.
A critical review of numerous clinical studies which studied the role of omega-3 LC-PUFA on blood pressure concluded that a significant reduction in blood pressure was seen in hypertensive subjects who consumed a high level of omega-3 LC-PUFA12.
In a large Italian clinical study, previous heart attack patients receiving omega-3 LC PUFA experienced a 20% reduction in total mortality, a 30% reduction in cardiovascular death, and a 45% reduction in sudden death at 3.5 years13,14.
Following weaning from breast milk, omega-3, LC-PUFA supplementation of infant formula (6 - 52 weeks of age) resulted in improved visual acuity in infants15.
Omega-3 LC-PUFA supplementation of infants (5 - 17 weeks of age) also improved cognitive development, as indicated by an improved scores for memory, problem-solving and discrimination at 18 months of age16.
Two clinical studies with school children showed that supplementation with omega-3 LC PUFA over 8 and 12 weeks significantly improved behavior in children with attention deficit hyperactivity disorder (ADHD)17,18.
In a clinical trial with older women the women given a combination of DHA (a component of omega-3 LC PUFA) and lutein scored significantly better on a verbal fluency test than women on placebo19.
Omega-3 LC PUFA given to postmenopausal women over 18 months significantly increased bone mineral density (BMD) of the lumbar spine and femoral neck bones compared to placebo20.
Cleland LG et. al. The role of fish oils in the treatment of rheumatoid arthritis. Drugs. 2003;63(9):835-53.
Goldberg RJ et. al. A meta-analysis of the analgesic effect of omega-3 polyunsaturated fatty acid supplementation for inflammatory joint pain. Pain 2007;129(1-2);210-23.
Berson EL et. al Further evaluation of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment: subgroup analyses. Archives of Ophthalmology 2004;122(9):1306-14.
Chua B et. al. Dietary fatty acids and the 5-year age-related maculopathy. Archives of Opththalmology 2006;124(7):981-6.
Chong EW et. al. Dietary omega-3 fatty acids and fish intake in the primary prevention of age-related macular degeneration:a systematic review and meta-analysis. Archives of Ophthalmology 2001;126(6):826.33.
Lucas M et. al. Effects of ethyl-eicosapentaenoic acid omega-3 fatty acid supplementation on hot flashes and quality of life among middle-aged women: a double-blind, placebo-controlled, randomized clinical trial. Menopause 2009;16(2):347-66.
Lavie CJ et.al. Omega-3 polyunsaturated fatty acids and cardiovascular disease. Journal of the American College of Cardiology 2009;54(7):585-94.
Deckelbaum RJ et. al. Conclusions and recommendations for the symposium, Beyond Cholesterol: Prevention and Treatment of Coronary Heart Disease with n-3 fatty acids. American Journal of Clinical Nutrition 2008. 87:6:2010s-2s.
Mozaffavian D. Effect of fish oil on heart rate in humans: a meta-analysis of randomized trials. Circulation 2005;112(13):1945-52.
Jacobson TA. Role of n-3 fatty acid in the treatment of hypertriglyceridemia and cardiovascular disease. American Journal of Clinical Nutrition 2008;87(6):1981sw-90s.
Balk EM et.al. Effects of omega-32 fatty acids on serum markers of cardiovascular disease risk: A systemic review. Atherosclerosis 2006;189:19-30.
Morris MC et. al. Does fish oil lower blood pressure? A meta-analysis of controlled trials. Circulation 1993;88(2):523-33.
Marchioli R et. al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction; time course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’ Infarty Miocardio (GISSI) – Prevenzione. Circulation 2002;105(6):1897-903.
Marchioli R et. al. Antiarrhythmic mechanism of n-3 PUFA and the results of the GISSI – Prevenzione trial. Journal of Membrane Biology 2005;206(2);177-28.
Birch EE et al. (2002) A randomized controlled trial of long-chain polyunsaturated fatty acid supplementation of formula in term infants after weaning at 6 wk of age. American Journal of Clinical Nutrition 75: 570-580.
Birch EE et al.(2000) A randomized controlled trial of early dietary supply of long-chain polyunsaturated fatty acids and mental development in term infants. Developmental Medical Child Neurology, 42:174-181.
Sorgi et al. Effects of an open-label pilot study with high-dose EPA/DHA concentrates on plasma phospholipids and behavior in children with attention deficit hyperactivity disorder. Nutrition Journal2007;6:16.
Richardson and Montgomery. The Oxford-Durham Study: A randomized, controlled trial of dietary supplementation with fatty acids in children with developmental coordination disorder. Pediatrics 2005;115:1360-1366.
Johnson et al. Cognitive findings of an exploratory trial of docosahexaenoic acid and lutein supplementation in older women. Nutritional Neuroscience 2008;11(2):75-83.
Kruger et. al. Calcium, gamma-linolenic acid, eicosapentaenoic acid in senile osteoporosis. Aging Clinical Experimental Research 1998;10(5):385-94.